Jansson Hannes, Oba Atsushi, Maekawa Aya, Villard Christina, Kobayashi Kosuke, Ono Yoshihiro, Engstrand Jennie, Kawano Fumihiro, Ito Hiromichi, Gilg Stefan, Inoue Yosuke, D'Souza Melroy A, Takahashi Yu
Division of Surgery and Oncology, Department of Clinical Science, Innovation and Technology, Karolinska Institutet, Stockholm, Sweden.
Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zraf019.
Resection outcomes for perihilar cholangiocarcinoma differ between Western and Eastern centres, but reasons behind these disparities remain unclear. This study aimed to compare current outcomes between a Western and an Eastern expert centre to identify prognostic factors.
Patients who underwent hepatobiliary resection for perihilar cholangiocarcinoma between 2010 and 2022 at Karolinska University Hospital (Stockholm, Sweden) and Cancer Institute Hospital (Tokyo, Japan) were retrospectively included. Primary outcome was overall survival. Secondary outcomes were disease-free survival, postoperative complications and 90-day mortality rate.
Two hundred and forty-nine patients were included (Cancer Institute Hospital n = 159, Karolinska n = 90). Median overall survival was 20.4 months at Karolinska and 52.0 months at Cancer Institute Hospital (P < 0.001). Median disease-free survival was 11.9 months at Karolinska and 32.4 months at Cancer Institute Hospital (P < 0.001). Advanced tumours, ASA class ≥III, poor differentiation and radial margin positivity were more common in the Western cohort. Treatment centre, T-status, N1-status, resection side, R1-status, age and carbohydrate antigen 19-9 were prognostic for overall survival. The Eastern cohort had a lower rate of postoperative complications (24.5%) and a lower mortality rate (2.5%) compared with the Western cohort (51.1% and 10.0%).
Advanced tumour stage and radial margin positivity contributed to poor long-term survival in the Western cohort. A higher burden of co-morbidity and a higher rate of extended resections with smaller remnant liver volume influenced the Western postoperative mortality rate.
肝门部胆管癌的切除结果在西方和东方中心之间存在差异,但这些差异背后的原因尚不清楚。本研究旨在比较西方和东方专家中心目前的治疗结果,以确定预后因素。
回顾性纳入2010年至2022年间在卡罗林斯卡大学医院(瑞典斯德哥尔摩)和癌症研究所医院(日本东京)接受肝门部胆管癌肝胆切除术的患者。主要结局是总生存期。次要结局是无病生存期、术后并发症和90天死亡率。
共纳入249例患者(癌症研究所医院159例,卡罗林斯卡90例)。卡罗林斯卡大学医院的中位总生存期为20.4个月,癌症研究所医院为52.0个月(P<0.001)。卡罗林斯卡大学医院的中位无病生存期为11.9个月,癌症研究所医院为32.4个月(P<0.001)。晚期肿瘤、美国麻醉医师协会(ASA)分级≥III级、低分化和切缘阳性在西方队列中更为常见。治疗中心、T分期、N1分期、切除侧、R1分期、年龄和糖类抗原19-9是总生存期的预后因素。与西方队列(51.1%和10.0%)相比,东方队列的术后并发症发生率(24.5%)和死亡率(2.5%)更低。
晚期肿瘤分期和切缘阳性导致西方队列的长期生存较差。较高的合并症负担和更大范围的切除术以及较小的残余肝体积影响了西方的术后死亡率。